News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website



Posted on: 12/14/2006

XERECEPT (corticorelin acetate injection), is an investigative drug that is currently being evaluated in Phase III clinical trials for the treatment of peritumoral brain edema (PBE):

Earlier this month, Celtic Pharma and Neurobiological Technologies, Inc. presented an interim report of an open-label extension study in a Phase III program for XERECEPT at the Society for Neuro-Oncology meeting in Orlando, Florida.  The report showed that 11 of 20 subjects were able to reduce their dexamethasone dosage during the four-week study, and two took no concomitant dexamethasone.  18 subjects (45%) showed baseline improvement or resolution of steroid-related side effects.

XERECEPT is being developed as a steroid-sparing alternative to dexamethasone for the treatment of PBE.  Two double-blind, placebo controlled studies are currently enrolling  to evaluate the drug?s long-term safety and tolerability.  The open-label study is available to patients who have already completed one of the two double-blind studies.

For more information, please visit

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557